Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

The company needs Rinvoq and another new immunology drug – recently-approved psoriasis therapy Skyrizi (risankizumab) – to help offset the expected declines in Humira sales once biosimilar ...

AbbVie bounced back after strong ... reaping the windfall of Humira, an immunology drug used to treat various conditions, including rheumatoid arthritis and plaque psoriasis.

This will allow Sandoz’s Humira biosimilar, and other biosimilar competitors, to launch after the $18.4 billion ... such as rheumatoid arthritis and psoriasis. Kavya Gopal, head of specialty ...

Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting ...